Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long Term Safety of Fezolinetant in Japanese Women With Hot Flashes
NCT06206421Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vasomotor symptoms comparing Fezolinetant with Placebo (2 arms). Primary endpoint: Number of participants with Adverse Events at 55 weeks. Started Feb 2024; status: completed.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT06206421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06206421.